Après la publication des résultats de l'essai clinique de la Women's Health Initiative
(WHI) sur l'association d'œstrogènes et de progestatifs,
1
l'opinion publique s'est braquée contre l'utilisation de cette combinaison pharmaceutique
chez les femmes postménopausées. Les protagonistes qui étaient en faveur de l'usage
des préparations combinées d'œstrogènes et de progestérones (et qui en souhaitaient
la commercialisation) ont profité du vide thérapeutique. C'était la chance qui n'arrivait
qu'une fois dans la vie. Les partisans de l'usage de ces préparations ont inventé
l'expression « bio-identique » pour en faire la promotion. Ils ont ainsi réussi un
coup de maître sur le plan du marketing, car l'expression semblait à fois scientifique
et naturelle.
- Rossouw J.E.
- Anderson G.L.
- Prentice R.L.
- LaCroix A.Z.
- Kooperberg C.
- Stefanick M.L.
- et al.
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal
results from the Women's Health Initiative randomized controlled trial. Writing Group
for the Women's Health Initiative Investigators.
JAMA.
2002;
288
:
321-333
To read this article in full you will need to make a payment
Subscribe to Journal of Obstetrics and Gynaecology Canada
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Références
- Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. Writing Group for the Women's Health Initiative Investigators.JAMA. 2002; 288: 321-333
- Ageless: The naked truth about bioidentical hormones.Crown Archetype, New York2006
- Bioidentical hormone therapy: a review.Menopause. 2004; 11: 356-367
- Bioidentical compounded hormones: a pharmacokinetic evaluation in a randomized clinical trial.Maturitas. 2013; 74: 375-382
- Micronised transdermal progesterone and endometrial response.Lancet. 1999; 354: 1447-1448
- A double-blind placebo-controlled study to evaluate the effect of progestelle progesterone cream on postmenopausal women.Menopause Int. 2009; 15: 63-69
- Effectiveness of compounded bioidentical hormone replacement therapy: an observational cohort study.BMC Women's Health. 2011; 11: 27-37
- The effects of compounded bioidentical transdermal hormone therapy on hemostatic, inflammatory, immune factors; cardiovascular biomarkers; quality-of-life measures; and health outcomes in perimenopausal and postmenopausal women.Int J Pharm Compd. 2013; 17: 74-85
- Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes (review).Cochrane Database Syst Rev. 2004; : CD002978
- Bioidentical progesterone cream for menopause-related vasomotor symptoms: is it effective?.Ann Pharmacother. 2013; 47: 112-116
- Compounded bioidentical menopausal hormone therapy.Fertil Steril. 2012; 98: 308-312
Article Info
Publication History
Published online: June 01, 2016
Identification
Copyright
Copyright © 2016 The Society of Obstetricians and Gynaecologists of Canada/La Société des obstétriciens et gynécologues du Canada. Published by Elsevier Inc. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- A Word About BioidenticalsJournal of Obstetrics and Gynaecology Canada Vol. 38Issue 8
- In BriefAfter publication of the findings in the Women's Health Initiative (WHI) combined estrogen-progestin trial,1 the public mood turned against the use of this pharmaceutical combination in postmenopausal women. Into the therapeutic void that followed leapt the protagonists who supported (and wished to market) compounded preparations of estrogens and progesterone. It was a once-in-a-generation opportunity. To assist in promoting the use of these preparations, their supporters coined the term “bioidentical.” It was a stroke of marketing genius because the word sounded both scientific and natural.
- Full-Text
- In Brief
